![Chemical Structure Chemical Structure](https://adipogen.com/pub/media/catalog/product/a/g/ag-cr1-3582.png)
Chemical Structure
R-848 [144875-48-9]
![Research Use Only](static/images/certificates/ruo.jpg)
AG-CR1-3582
Overview
- SupplierAdipoGen Life Sciences
- Product NameR-848 [144875-48-9]
- Delivery Days Customer10
- CAS Number144875-48-9
- CertificationResearch Use Only
- Estimated Purity>98%
- Molecular FormulaC17H22N4O2
- Molecular Weight314.4
- Scientific DescriptionChemical. CAS: 144875-48-9. Formula: C17H22N4O2. MW: 314.4. Synthetic. Immune response modifier. Potent antitumor and antiviral compound. Stimulates antibody secretion and cytokine production. Used as adjuvant to increase the effectiveness of vaccines. Potent and selective synthetic ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human. Activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway and leads to the induction of NF-kappaB. NLRP3/NALP3 inflammasome activator, independent of TLRs and RIG-I. Upregulator of the opioid growth factor receptor. Used in the treatment of skin lesions such as herpes simplex virus. - Immune response modifier. Potent antitumor and antiviral compound [1, 3, 10, 11, 13, -16]. Stimulates antibody secretion and cytokine production [2]. Used as adjuvant to increase the effectiveness of vaccines [2, 7, 9, 10]. Potent and selective synthetic ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human [4-6]. Activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway and leads to the induction of NF-kappaB [4]. NLRP3/NALP3 inflammasome activator, independent of TLRs and RIG-I [8]. Upregulator of the opioid growth factor receptor [12]. Used in the treatment of skin lesions such as herpes simplex virus [16].
- SMILESCCOCC1=NC2=C(N1CC(C)(C)O)C1=C(C=CC=C1)N=C2N
- Storage Instruction2°C to 8°C,-20°C
- UNSPSC12352200
References
- Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod: T.L. Wagner, et al.; Cell Immunol. 191, 10 (1999)
- Adjuvant activities of immune response modifier R-848: comparison with CpG ODN: J.P. Vasilakos, et al.; Cell Immunol. 204, 64 (2000)
- The immune response modifier resiquimod mimics CD40-induced B cell activation: G.A. Bishop, et al.; Cell. Immunol. 208, 9 (2001)
- Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002)
- Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848: M. Jurk, et al.; Nat. Immunol. 3, 499 (2002)
- Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8: K.B. Gorden, et al.; J. Immunol. 174, 1259 (2005)
- TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848): R.D. Weeratna, et al.; Vaccine 23, 5263 (2005)
- Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3: T.D. Kanneganti, et al.; Nature 440, 233 (2006)
- Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination: R. Ma, et al.; BBRC 361, 537 (2007)
- Resiquimod and other immune response modifiers as vaccine adjuvants: M.A. Tomai, et al.; Expert Rev. Vaccines 6, 835 (2007) (Review)